Page 113 - Drug Class Review

Drug Effectiveness Review Project
Alzheimer classification: Moderate-Severe
Groups similar at baseline: Yes

Health Outcome Measures:

donepezil placebo 74.0 73.3 61.0 61.1 11.97 11.72 Primary Outcome Measures: CIBIC-plus Secondary Outcome Measures: sMMSE; SIB; DAD; ADL; IADL; modified IADL (IADL+); PSMS+; NPI; FRS; CSS; Caregiver SF-36; CAUST Timing of assessments: Baseline and weeks 4, 8, 12, 18 and 24 DON-treated patients had a significantly slower decline of measures of daily functioning than placebo-treated patients; differences were +6.83 (P < 0.001) in IADL, +1.32 (P = 0.0015) in PSMS, and 8.24 in DAD (P < 0.0001) at week 24 Behavioral and neuropsychiatric symptoms,

• • • •

Final Report Update 1 Authors: Feldman et al. Year: 2001 POPULATION CHARACTERISTICS: Mean age (years): Sex (% female): Other germane population qualities: Mean baseline sMMSE score • OUTCOME ASSESSMENT: RESULTS: Alzheimer's Drugs